Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motixafortide, Cemiplimab, Gemcitabine, and Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma
NCT04543071Phase 2Active, not recruiting
- Sponsor
- Columbia University
- Start
- Nov 2020
- Primary completion
- Jun 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of motixafortide, cemiplimab in pancreatic adenocarcinoma (PDAC), sponsored by Columbia University. Started Nov 2020; status: active, not recruiting.
02
Drugs
motixafortidecemiplimab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04543071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04543071.